Details of the Drug Combination

General Information of Drug Combination (ID: DC3W3HZ)

Drug Combination Name
Ublituximab Umbralisib
Indication
Disease Entry Status REF
Chronic lymphocytic leukaemia; Non-hodgkin lymphoma Phase 1 [1]
Component Drugs Ublituximab   DMHTY9W Umbralisib   DMYRBO1
Antibody N.A.

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Ublituximab
Disease Entry ICD 11 Status REF
Multiple sclerosis 8A40 Approved [2]
Chronic lymphocytic leukaemia 2A82.0 Phase 3 [3]
Lymphoma 2A80-2A86 Phase 1/2 [4]
Nodal marginal zone lymphoma 2A85.0 Phase 1/2 [4]
Ublituximab Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Leukocyte surface antigen Leu-16 (CD20) TTUE541 CD20_HUMAN . [7]
------------------------------------------------------------------------------------
Indication(s) of Umbralisib
Disease Entry ICD 11 Status REF
Follicular lymphoma 2A80 Approved [5]
Marginal zone lymphoma 2A85.0 Approved [5]
Diffuse large B-cell lymphoma 2A81 Phase 2/3 [6]
Chronic lymphocytic leukaemia 2A82.0 Phase 2 [3]
Non-hodgkin lymphoma 2B33.5 Phase 2 [3]
Umbralisib Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
PI3-kinase delta (PIK3CD) TTGBPJE PK3CD_HUMAN Inhibitor [5]
Casein kinase I epsilon (CSNK1E) TTA8PLI KC1E_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------

References

1 FDA Drug Development and Drug Interactions
2 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761238.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
6 ClinicalTrials.gov (NCT02793583) Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma (UNITY-NHL). U.S. National Institutes of Health.
7 The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenstr m macroglobulinemia. Haematologica. 2015 Apr;100(4):e147-51.